Edition:
United Kingdom

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

18.05USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$18.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
300,849
52-wk High
$18.75
52-wk Low
$9.30

Chart for

About

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $489.96
Shares Outstanding(Mil.): 46.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Sucampo Pharmaceuticals Received Notification From FDA That It Has Extended PDUFA Goal Date By 3 Months

* SUCAMPO PHARMACEUTICALS - ON DEC 28, RECEIVED NOTIFICATION FROM U.S. FDA THAT IT HAS EXTENDED PDUFA GOAL DATE BY 3 MONTHS FOR SNDA FOR LUBIPROSTONE

02 Jan 2018

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

26 Dec 2017

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

26 Dec 2017

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

26 Dec 2017

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

26 Dec 2017

BRIEF-Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln

* MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION

26 Dec 2017

Mallinckrodt to buy Sucampo Pharmaceuticals for about $1.2 bln

Dec 26 Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc in a deal valued at about $1.2 billion to gain access to its constipation drug, Amitiza.

26 Dec 2017

BRIEF-ING Groep NV Reports 6.70 Pct Passive Stake In Sucampo Pharmaceuticals As Of Dec 7 - SEC Filing

* REPORTS A 6.70 PCT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DEC 7 - SEC FILING Source text: (http://bit.ly/2yseEW4) Further company coverage:

14 Dec 2017

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage:

08 Dec 2017

Sucampo weighs sale after fielding takeover interest: Bloomberg

Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

07 Dec 2017

Earnings vs. Estimates